Overview
- Editors:
-
-
Randall E. Harris
-
The Ohio State University College of Medicine and School of Public Health, Columbus, USA
Access this book
Other ways to access
About this book
The revelation that aspirin and aspirin-like compounds have notableantineo plastic properties has revolutionized cancer research. COX-2 Blockade in Cancer Prevention and Therapy chronicles the evidence and presents exciting new op portunities for the use of cyclooxygenase-2 (COX-2) blockade in the prevention and treatment of cancer. The text is divided broadly into five areas. First, an historical overview documents the scientific discovery ofCOX-2 and the pharma ceutical development of nonsteroidal anti-inflammatory drugs (NSAIDs) designed for selective COX-2 inhibition. The process by which essential poly unsaturated fatty acids (PUF As) stimulate prostaglandin biosynthesis and cancer development, and its interruption by COX-2 inhibition, is elucidated. This is followed by a section on the epidemiology of NSAIDs and cancers of the colon and breast, and other anatomic sites. These chapters reflect significant cancer protection owing to the regular use of common NSAIDs such as aspirin and ibuprofen. A section on animal models of carcinogenesis presents comprehensive evidence that general NSAIDs inhibit a variety of malignant neoplasms in vivo, and highlights recent findings which show that COX-2 blocking agents produce striking chemopreventive effects against colon cancer and breast cancer as well as other malignancies. Genetic models are presented confirming the critical role of COX-2 in carcinogenesis. Section IV then discusses the molecular biology of COX -2 vis-a-vis the role of COX -2 and, to a lesser extent, COX -1, in modulating a number of important processes in molecular carcinogenesis such as mutagen esis, cell division, angiogenesis, cell differentiation, and apoptosis.
Table of contents (20 chapters)
-
-
-
Epidemiology of NSAIDs and Cancer
-
-
- Michael J. Thun, S. Jane Henley
Pages 35-55
-
-
Animal Models of Carcinogenesis
-
-
- Bandaru S. Reddy, Chinthalapally V. Rao
Pages 71-83
-
- Hussein M. Abou-Issa, Galal A. Alshafie, Randall E. Harris
Pages 85-98
-
-
- Jay Whelan, Michael F. McEntee
Pages 117-145
-
-
Molecular Biology of COX-2
-
Front Matter
Pages 157-157
-
- Rajnish A. Gupta, Raymond N. DuBois
Pages 159-169
-
- Byeong-Churl Jang, Timothy Hla
Pages 171-184
-
- Alane T. Koki, Kathleen M. Leahy, Janet M. Harmon, Jaime L. Masferrer
Pages 185-203
-
- Jeanette A. Richards, Robert W. Brueggemeier
Pages 205-224
-
-
- Linda C. Hsi, Thomas E. Eling
Pages 245-255
Reviews
"...a must, not only for oncologists but also for every family doctor, who is often the first to see a patient with a cancerous or precancerous or precancerous condition." -Lancet Oncology
"This comprehensive and up-to-date monograph demonstrates how COX-2 inhibitors and other NSaids reduce the risk of most cancers and provides cancer investigators by a clear and authoritative guide leading to the development of novel angst with significant antineoplastic properties." -Neoplasma
Editors and Affiliations
-
The Ohio State University College of Medicine and School of Public Health, Columbus, USA
Randall E. Harris